Pages
Products
Nivolumab Stable Cell Line - CHO-K1

Nivolumab Stable Cell Line - CHO-K1

Cat.No. :  CSC-BS0004 Host Cell:  CHO-K1

Inquire for Price

Cell Line Information

Safety and Packaging

Cat. No. CSC-BS0004
Description This cell line is engineered to stably produce Nivolumab which is a monoclonal antibody against human PDCD1/PD1.
Biosimilar Nivolumab
Host Cell CHO-K1
Host Cell Species Cricetulus griseus (Chinese hamster)
Stability Validated for at least 10 passages
Application

1. Biosimilar Development

2. Large-Scale Biomanufacturing

3. Preclinical Research

4. Drug Development and Testing

Growth Conditions 37° C, 5% CO2
Quality Control Negative for bacteria, yeast, fungi and mycoplasma.
Shipping Dry ice
Storage Liquid nitrogen
Mycoplasma Negative
Format One frozen vial containing millions of cells
Storage Liquid nitrogen
Safety Considerations

The following safety precautions should be observed.

1. Use pipette aids to prevent ingestion and keep aerosols down to a minimum.

2. No eating, drinking or smoking while handling the stable line.

3. Wash hands after handling the stable line and before leaving the lab.

4. Decontaminate work surface with disinfectant or 70% ethanol before and after working with stable cells.

5. All waste should be considered hazardous.

6. Dispose of all liquid waste after each experiment and treat with bleach.

Ship Dry ice
Quick Inquiry

Publications

Q & A

Customer Reviews

Customer Q&As
What is Nivolumab?

A: Nivolumab is a type of cancer treatment drug called immunotherapy. It's a treatment for a number of different types of cancer.

What is the mechanism of action of Nivolumab?

A: Nivolumab works by blocking the interaction between PD-1 and its ligands, leading to the activation of T-cells and the destruction of cancer cells.

What type of cancer is nivolumab used for?

A: Nivolumab is used alone or with other drugs to treat certain types of esophageal cancer, stomach cancer, colorectal cancer, gastroesophageal junction cancer, non-small cell lung cancer, renal cell carcinoma, melanoma, hepatocellular carcinoma, Squamous cell carcinoma of the head and neck and urothelial carcinoma.

How do I create a stable cell line that produces Nivolumab?

A: Developing a Nivolumab stable cell line requires genetic engineering techniques that insert the PD-1 receptor sequence into the CHO-K1 cell genome. The engineered cells are then selected, screened, and cultured to obtain a pure, robust cell population that secrete Nivolumab.

Why use CHO-K1 cells?

A: CHO-K1 cells are a popular choice for antibody production due to their ability to grow and divide rapidly, their capacity for high-density culture, and their adaptability to a variety of culture conditions.

Ask a Question

If your question is not addressed through these resources, you can fill out the online form below and we will answer your question as soon as possible.

Customer Reviews
Reduces the time and cost of Nivolumab development

Great buy! The use of stable cell lines reduces the time and cost of Nivolumab development, as well as ensuring consistency in the quality of the Nivolumab.

United States

05/12/2021

Effective

The Nivolumab stable cell lines can produce large quantities of Nivolumab consistently over an extended period. I recommend it.

United Kingdom

08/15/2021

Invaluable tool

Great! This Nivolumab Stable Cell Line is an invaluable tool in my drug development.

United States

10/09/2021

Write a Review

Write a review of your use of Biogene products and services in your research. Your review can help your fellow researchers make informed purchasing decisions.

Needs improvement

Satisfaction

General satisfaction

Very satisfaction